Aquestive Therapeutics (AQST) Soars 3.97% on FDA NDA Acceptance

Aquestive Therapeutics (AQST) shares rose to their highest level since December 2024 today, with an intraday gain of 3.97%.

The strategy of buying AQST shares after they reach a recent high and selling them one week later resulted in no returns over the past five years. The strategy had a CAGR of 0.00% and an excess return of 100.00%, but the benchmark return was -100.00%, indicating that the strategy underperformed the market significantly. Additionally, the strategy had a maximum drawdown of 0.00% and volatility of 0.00%, which suggests that the strategy had no risk or returns.

Aquestive Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for Anaphylm™, a novel product. This event is significant as FDA approval processes can heavily influence stock prices. The acceptance of the NDA for Anaphylm™ is a positive development for the company, as it brings the product one step closer to potential market approval. Investors are likely to view this news favorably, as it indicates progress in the company's pipeline and the potential for future revenue growth.

During the Q1 2025 earnings call, Aquestive Therapeutics Inc highlighted challenges in navigating revenue declines, which can impact investor sentiment and stock performance. The company's revenue decline may raise concerns among investors about the company's financial health and its ability to generate sustainable growth. However, the company's management may have provided insights into strategies to address these challenges, which could help mitigate some of the negative sentiment.